TY - JOUR
T1 - Proteomic and genetic analyses of influenza A viruses identify pan-viral host targets
AU - Haas, Kelsey M.
AU - McGregor, Michael J.
AU - Bouhaddou, Mehdi
AU - Polacco, Benjamin J.
AU - Kim, Eun Young
AU - Nguyen, Thong T.
AU - Newton, Billy W.
AU - Urbanowski, Matthew
AU - Kim, Heejin
AU - Williams, Michael A.P.
AU - Rezelj, Veronica V.
AU - Hardy, Alexandra
AU - Fossati, Andrea
AU - Stevenson, Erica J.
AU - Sukerman, Ellie
AU - Kim, Tiffany
AU - Penugonda, Sudhir
AU - Moreno, Elena
AU - Braberg, Hannes
AU - Zhou, Yuan
AU - Metreveli, Giorgi
AU - Harjai, Bhavya
AU - Tummino, Tia A.
AU - Melnyk, James E.
AU - Soucheray, Margaret
AU - Batra, Jyoti
AU - Pache, Lars
AU - Martin-Sancho, Laura
AU - Carlson-Stevermer, Jared
AU - Jureka, Alexander S.
AU - Basler, Christopher F.
AU - Shokat, Kevan M.
AU - Shoichet, Brian K.
AU - Shriver, Leah P.
AU - Johnson, Jeffrey R.
AU - Shaw, Megan L.
AU - Chanda, Sumit K.
AU - Roden, Dan M.
AU - Carter, Tonia C.
AU - Kottyan, Leah C.
AU - Chisholm, Rex L.
AU - Pacheco, Jennifer A.
AU - Smith, Maureen E.
AU - Schrodi, Steven J.
AU - Albrecht, Randy A.
AU - Vignuzzi, Marco
AU - Zuliani-Alvarez, Lorena
AU - Swaney, Danielle L.
AU - Eckhardt, Manon
AU - Wolinsky, Steven M.
AU - White, Kris M.
AU - Hultquist, Judd F.
AU - Kaake, Robyn M.
AU - García-Sastre, Adolfo
AU - Krogan, Nevan J.
N1 - Publisher Copyright:
© 2023, Springer Nature Limited.
PY - 2023/12
Y1 - 2023/12
N2 - Influenza A Virus (IAV) is a recurring respiratory virus with limited availability of antiviral therapies. Understanding host proteins essential for IAV infection can identify targets for alternative host-directed therapies (HDTs). Using affinity purification-mass spectrometry and global phosphoproteomic and protein abundance analyses using three IAV strains (pH1N1, H3N2, H5N1) in three human cell types (A549, NHBE, THP-1), we map 332 IAV-human protein-protein interactions and identify 13 IAV-modulated kinases. Whole exome sequencing of patients who experienced severe influenza reveals several genes, including scaffold protein AHNAK, with predicted loss-of-function variants that are also identified in our proteomic analyses. Of our identified host factors, 54 significantly alter IAV infection upon siRNA knockdown, and two factors, AHNAK and coatomer subunit COPB1, are also essential for productive infection by SARS-CoV-2. Finally, 16 compounds targeting our identified host factors suppress IAV replication, with two targeting CDK2 and FLT3 showing pan-antiviral activity across influenza and coronavirus families. This study provides a comprehensive network model of IAV infection in human cells, identifying functional host targets for pan-viral HDT.
AB - Influenza A Virus (IAV) is a recurring respiratory virus with limited availability of antiviral therapies. Understanding host proteins essential for IAV infection can identify targets for alternative host-directed therapies (HDTs). Using affinity purification-mass spectrometry and global phosphoproteomic and protein abundance analyses using three IAV strains (pH1N1, H3N2, H5N1) in three human cell types (A549, NHBE, THP-1), we map 332 IAV-human protein-protein interactions and identify 13 IAV-modulated kinases. Whole exome sequencing of patients who experienced severe influenza reveals several genes, including scaffold protein AHNAK, with predicted loss-of-function variants that are also identified in our proteomic analyses. Of our identified host factors, 54 significantly alter IAV infection upon siRNA knockdown, and two factors, AHNAK and coatomer subunit COPB1, are also essential for productive infection by SARS-CoV-2. Finally, 16 compounds targeting our identified host factors suppress IAV replication, with two targeting CDK2 and FLT3 showing pan-antiviral activity across influenza and coronavirus families. This study provides a comprehensive network model of IAV infection in human cells, identifying functional host targets for pan-viral HDT.
UR - http://www.scopus.com/inward/record.url?scp=85173073553&partnerID=8YFLogxK
U2 - 10.1038/s41467-023-41442-z
DO - 10.1038/s41467-023-41442-z
M3 - Article
C2 - 37758692
AN - SCOPUS:85173073553
SN - 2041-1723
VL - 14
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 6030
ER -